Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Elranatamab→

Elranatamab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2408850-14-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
BCMA-directed CD3 T-cell-engaging bispecific antibodyantineoplastic biologic
Mechanism of action
Binds B-cell maturation antigen (BCMA) on plasma cells and multiple myeloma cells and CD3 on T cells, bringing T cells into proximity with BCMA-expressing tumour cells and inducing T-cell-mediated cytolysis.
Indications / reported uses
  • Treatment of adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, under the US product indication; current label and local authorisation criteria apply

Sources: US DailyMed — ELREXFIO (elranatamab-bcmm) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Elranatamab Environmental Risk Assessment (ERA) (the Elranatamab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.